IP Library Granted Patent US 7,390,892
Granted Patent B2
US 7,390,892 · App. 10/499,554 · Granted Jun 24, 2008

Nucleic acids encoding novel cyclic GMP dependent protein kinases from

Assignee: Merial Limited
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,390,892
App. No.
10/499,554
Granted
Jun 24, 2008
Kind
B2
Abstract

The present invention relates to novel protozoal cyclic GMP dependent protein kinases and genes encoding same that have been isolated from Eimeria maxima and Plasmodium falciparum . Nucleic acid molecules having sequences that encode such proteins as well as antibodies raised against such proteins are also disclosed. These enzymes may be used in screening assays to identify potential antiprotozoal agents. As well, methods to obtain such nucleic acid molecules, proteins, antibodies and inhibitor are also provided as are therapeutic compositions comprising such nucleic acid molecules, proteins, antibodies and inhibitors as well as their use to protect animals from disease caused by parasites such as Eimeria maxima and Plasmodium falciparum.

Claims (9)

1. An isolated nucleic acid molecule, comprising a sequence of nucleotides that encode an Eimeria maxima cGMP dependent protein kinase (PKG), wherein the sequence of nucleotides is selected from the group consisting of:

(a) a sequence of nucleotides that encodes an Eimeria maxima cGMP dependent protein kinase (PKG) comprising the nucleotide sequence of SEQ ID NO: 1; and

(b) a sequence of nucleotides that encodes an Eimeria maxima cGMP dependent protein kinase (PKG) comprising the amino acid sequence of SEQ ID NO:2.

2. A recombinant nucleic acid molecule comprising a nucleic acid sequence according to claim 1 operatively linked to expression control sequences enabling expression of said nucleic acid sequence.

3. An isolated host cell transformed with the recombinant nucleic acid molecule according to claim 2 .

4. An immunogenic composition, comprising a recombinant nucleic acid molecule according to claim 2 , together with a pharmaceutically acceptable carrier.

5. An immunogenic composition, comprising the nucleic acid molecule of claim 1 , together with a pharmaceutically acceptable carrier.

6. An isolated nucleic acid molecule that encodes an Eimeria maxima cGMP dependent protein kinase (PKG) comprising the amino acid sequence of SEQ ID NO:2.

7. The isolated nucleic acid molecule of claim 6 wherein the nucleic acid molecule comprises the nucleotide sequence of SEQ ID NO: 1.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 16, 2016
From: MERIAL LIMITED
To: MERIAL, INC.
Reel/Frame 039039/0211 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 26, 2007
From: MERCK AND CO.
To: MERIAL LIMITED
Reel/Frame 018811/0827 →
Continuity (2)
Provisional Application 6034281600 · Dec 20, 2001
Related Publication 20050147628A1 · Jul 7, 2005